\
&
Contact us
\
&
Contact us
This was 1 month ago
LocationOnline
ProgrammesThe UnILiON Brokerage Event focuses on Cluster 2 of Horizon Europe (Culture, Creativity and Inclusive Society). The event seeks to foster collaboration and knowledge sharing among public and private sector stakeholders in preparation for the upcoming Cluster 2 Horizon Europe calls with 2026 deadlines.
Participants may register as either attendees to listen to project pitches or as pitch presenters to deliver short presentations on project ideas or relevant expertise.
The deadline for registration and submitting pitches is 22 January 2026 and you can do this by filling in this webform. Pitch presentations must be returned to: elissa.daher@unibz.it.
Background: UniLion is network of universities based in Europe and Japan. The network represents an arena of exchange where the participants share information, nurture collaboration and act as information multipliers towards the represented organisations.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
